4/6/26 - sorry for the wait! | Martin Shkreli

The podcast centers on pharmaceutical stocks, peptide use, and investment strategies, with Martin Shkreli and others analyzing various companies and market trends. Discussions include Celeno's acquisition by Neurocrin, Lightwave Logic's photonic devices, and Amgen's Repath, alongside commentary on Cristexa's revenue growth. The hosts delve into the potential of Viking Therapeutics (VKTX) and Vaxcite, assessing their market positions and future prospects. A significant portion of the conversation addresses the use of peptides, with the hosts sharing personal experiences and opinions, while also touching on the risks and benefits. Additionally, the podcast explores the potential of optical computing and QCLS, estimating timelines for their commercial viability and impact on GPU technology.

Outlines

Part 1: Biotech News, Market Moves

Part 2: Pharma Analysis, Tech, and Personal Health

Part 3: Peptides, Prison, and Drug Data

Part 4: Trading Tools, AI, and Business Operations

Sign in to continue reading, translating and more.

Continue

4/6/26 - sorry for the wait!

Martin Shkreli

Part 1: Biotech News, Market Moves

Martin Shkreli's Return, Celeno Acquisition, and Cristexa's Missed Opportunity

Peptide Use, Pharmacology Ignorance, and Kodiak's Stock Comeback

Maritide Discussion, Mic Issues, and Amgen's Potential

Part 2: Pharma Analysis, Tech, and Personal Health

Repath's Success, Cough Suppressants, and Lean Ingredients

Venture Capital, NVIDIA, and Memory Stocks Analysis

Viking Therapeutics, GLP Trials, and "Bud Bud"

Part 3: Peptides, Prison, and Drug Data

Peptide Injections, True Tide, and Prison Experiences

AGI Optimism, Prison Reading, and Viking's GLP Data

GLP Safety, Discontinuation, and Vaxcyte's Pneumococcal Vaccine

Part 4: Trading Tools, AI, and Business Operations

Goodell Terminal, Cullinan Therapeutics, and Crude Oil Prices

Apsi, Sam Altman, and Spruce Updates

Spruce, Office Space, and Legal Matters

4/6/26 - sorry for the wait!

Martin Shkreli

Part 1: Biotech News, Market Moves

00:33Martin Shkreli's Return, Celeno Acquisition, and Cristexa's Missed Opportunity

Martin Shkreli's Return, Celeno Acquisition, and Cristexa's Missed Opportunity

07:24Peptide Use, Pharmacology Ignorance, and Kodiak's Stock Comeback

Peptide Use, Pharmacology Ignorance, and Kodiak's Stock Comeback

19:20Maritide Discussion, Mic Issues, and Amgen's Potential

Maritide Discussion, Mic Issues, and Amgen's Potential

Part 2: Pharma Analysis, Tech, and Personal Health

27:48Repath's Success, Cough Suppressants, and Lean Ingredients

Repath's Success, Cough Suppressants, and Lean Ingredients

39:51Venture Capital, NVIDIA, and Memory Stocks Analysis

Venture Capital, NVIDIA, and Memory Stocks Analysis

2:57:03Viking Therapeutics, GLP Trials, and "Bud Bud"

Viking Therapeutics, GLP Trials, and "Bud Bud"

Part 3: Peptides, Prison, and Drug Data

3:10:53Peptide Injections, True Tide, and Prison Experiences

Peptide Injections, True Tide, and Prison Experiences

3:23:45AGI Optimism, Prison Reading, and Viking's GLP Data

AGI Optimism, Prison Reading, and Viking's GLP Data

3:37:05GLP Safety, Discontinuation, and Vaxcyte's Pneumococcal Vaccine

GLP Safety, Discontinuation, and Vaxcyte's Pneumococcal Vaccine

Part 4: Trading Tools, AI, and Business Operations

3:50:06Goodell Terminal, Cullinan Therapeutics, and Crude Oil Prices

Goodell Terminal, Cullinan Therapeutics, and Crude Oil Prices

4:04:11Apsi, Sam Altman, and Spruce Updates

Apsi, Sam Altman, and Spruce Updates

6:19:35Spruce, Office Space, and Legal Matters

Spruce, Office Space, and Legal Matters